Work

TFH lymphomas: the times they aza-changin’?

Year: 2019

Type: article

Abstract: In this issue of Blood, O’Connor and colleagues(1) report a phase 1 study of romidepsin combined with oral azacytidine in patients with relapsed/refractory (R/R) lymphomas, including complete remissions among 3 patients with angioimmunoblastic T-cell lymphoma (AITL) and single patients with multiple other lymphoma subsets.

Source: Blood

DOI: 10.1182/blood.2019002806

Authors: David M. Weinstock, Steven M. Horwitz

Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2982098820

FWCI: 0.184

Cites: 10

Cited by: 1

Related to: 10